The Evira Study: Additional Support During Obesity Treatment

NCT06836284 · Recruiting

Last updated 2026-05-28

The Evira Study tests whether additional support helps children with obesity better follow their treatment plan.

Status Recruiting Currently enrolling participants.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 40 people Planned (estimated).

Who can join Ages 12–17 · all sexes

Timeline Started 2026-02 · est. completion 2027-05

Where 2 sites · Sweden

What this study is testing ClinicalTrials.gov NCT06836284 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to evaluate the effect of adding a digi-physical treatment tool as a complement to the local treatment with obesity medication in adolescents with obesity. The main question it aims to answer is: \- Can a combination of a digi-physical treatment tool and obesity medication improve treatment outcomes for patients with obesity compared to patients treated with obesity medications alone? This is a randomized controlled two-arm multicenter study where participants will be randomized to the intervention group (digi-physical treatment+medication) or control group (medication only). Participants will be followed for six months.

Treatments tested

Digi-physical treatment tool, Evira Device

A digi-physical treatment tool named Evira will be used to provide behavioral treatment.
Obesity medication with liraglutide or semaglutide Drug

Obesity medication with liraglutide or semaglutide according to the clinic's standard procedure

Main thing measured	Change in BMI SDS
Sponsor	Karolinska Institutet
Conditions studied	Childhood Obesity, Treatment Adherence
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06836284 ↗